drugset / Trial / NCT04200404
A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, open-label study of CS1001 in combination with regorafenib in participants with advanced or refractory cancers. There will be a dose escalation portion in "allcomers"to find a suitable dose of regorafenib for combination use with CS1001. This study will also enroll participants with specific tumor types in the phase II part of the study to assess the efficacy, pharmacokinetics and safety of the combined regimen (RP2D of regorafenib + CS 1001)
Timeline
- Start
- 2019-12-13
- Primary completion
- 2021-05-13
- Completion
- 2021-08-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | — | Oral |
| Subject | Sugemalimab | Monoclonal antibody | — | Intravenous |